Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout
The program that was once the crown jewel in Merck’s 2019 buyout of Peloton Therapeutics is one step closer to winning an FDA approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
